Anaptysbio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

28 Apr 2026

ANAB

10-K/A: AnaptysBio Files 10-K/A Amendment, Updates Governance and Compensation

AnaptysBio amends its 2025 annual report to include details on board composition changes, executive compensation, and related party transactions.

NASDAQ

3 Mar 2026

ANAB

Anaptysbio, INC

10-K: AnaptysBio Reports Strong Jemperli Sales, Plans Two-Company Split

AnaptysBio, a clinical-stage biotechnology company, announced plans to separate into two independent public entities, reporting significant Jemperli sales growth and positive Phase 2b rheumatoid arthritis trial data for rosnilimab.

NASDAQ

27 Feb 2025

ANAB

Anaptysbio, INC

10-K: AnaptysBio Reports Positive Phase 2b Rosnilimab Results, Advances Immunology Pipeline

AnaptysBio achieved key clinical milestones with its lead drug candidate, rosnilimab, and continues to advance its portfolio of immunology therapeutics.

NASDAQ

11 Mar 2024

ANAB

Anaptysbio, INC

10-K: AnaptysBio's 2023 Annual Report: Focus on Immunology Therapeutics and Pipeline Advancement

AnaptysBio's 2023 annual report highlights its focus on developing innovative immunology therapeutics, with key updates on its clinical-stage checkpoint agonist programs and strategic collaborations.